Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593071 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,330
- Enrollment target
NCT02593071: Completed Phase 2 study, sponsored by Novavax.
NCT02593071 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 1,330 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (900% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593071, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,330 participants
- Enrollment target
Study Summary
This study will enroll subjects who received the RSV F vaccine or placebo in the earlier study (RSV-E-201, Year 1) and re-randomize them to receive either vaccine or placebo in a second season. This design will permit evaluation of the safety and immunogenicity of revaccination in a second RSV season, and the safety and immunogenicity of revaccination over two years.
Primary Outcome
Derived/calculated endpoints based on these data will include: * Geometric mean concentration as EU (GMEU) * Geometric mean ratio (GMR) * Seroresponse rate (SRR) * Proportion of subjects with two (2)- and 4-fold seroconversion rates ( SCR2 and SCR4, respectively)
Interventions
- BIOLOGICAL RSV-F Vaccine
- BIOLOGICAL Phosphate Buffer Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,330 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
What the finished NCT02593071 record still lists
NCT02593071 is an interventional study that assigns participants to a tested intervention. Its 1,330 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (900% higher).
The record links to 0 conditions, and to 2 interventions - of which RSV-F Vaccine is the first listed.
NCT02593071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02593071 about?
NCT02593071 is a clinical study titled "Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.". This study will enroll subjects who received the RSV F vaccine or placebo in the earlier study (RSV-E-201, Year 1) and re-randomize them to receive either vaccine or placebo in a second season. This design will permit evaluation of the safety and immunogenicity of revaccination in a second RSV seaso...
What is the current status of trial NCT02593071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,330 participants. The study started on 2015-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02593071?
The interventions under investigation include: RSV-F Vaccine (BIOLOGICAL), Phosphate Buffer Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593071?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02593071's enrollment target sits among peer trials
1,330 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05536011 · 1,329 participants
WAKIX® (Pitolisant) Pregnancy Registry
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia